Gastric Cancer Clinical Trial
Official title:
Billroth-II Modified and Roux-en-Y Reconstruction After Distal Gastrectomy for Gastric Cancer: an Open-label Randomized Control Trial
There are Billroth-I, Billroth-II, Billroth-II with Braun, and Roux-en-Y reconstruction after distal gastrectomy. Hypothesis: Billroth-II modified method is non-inferior to Roux-en-Y method in terms of reducing reflux esophagitis after distal gastrectomy for gastric cancer patients.
Status | Recruiting |
Enrollment | 320 |
Est. completion date | April 30, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients confirmed with gastric cancer - Indicated for radical distal gastrectomy (cT1 to cT4a, any N, M0; according to AJCC/UICC 8th TNM staging for gastric cancer) - Age from 18- to 80-year-old - Agreed to participate in study with written inform consent Exclusion Criteria: - Pregnant patients - An American Society of Anesthesiology (ASA) score of higher than 4 - Concurrent cancer or history of previous other cancers - Previous gastrectomy - Complications including bleeding, perforation required emergency gastrectomy |
Country | Name | City | State |
---|---|---|---|
Vietnam | University Medical Center Ho Chi Minh City | Ho Chi Minh City |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Ho Chi Minh City (UMC) |
Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reflux esophagistis | Findings of reflux esophagitis according to Los Angeles classification via endoscopy | on the 12th month after surgery | |
Secondary | Early complications | Rate of any complications happened intraoperative and 30-days post-operative | 30 days after surgery | |
Secondary | Operative time | Time from first incision to finishing abdomen closure, measured by surgical nurse | Intraoperative | |
Secondary | Time for making anastomosis | Time from jejunal stapler opening (for B-II) or from jejunal separating (for R-II) to finishing enhancing suture (including duodenal stump enhancement) | Intraoperative | |
Secondary | Blood loss | Weighing of sucked blood and gauze, minus weighing of dry gauze | Intraoperative | |
Secondary | Length of post-operative hospital stay | Number of days from date of surgery until date of discharge or mortality | 30 days after surgery or until mortality | |
Secondary | Post gastrectomy syndromes | Rate of post gastrectomy syndromes after gastrectomy | from 30 days to 1 years after surgery | |
Secondary | Bodyweight | Changing of patient's weight at the follow-up time compare to weight before surgery | on the 3rd, 6th, and 12th month after surgery | |
Secondary | Serum total protein | Changing of patient's serum total protein at the follow-up time compare to serum protein before surgery | on the 3rd, 6th, and 12th month after surgery | |
Secondary | Serum albumin | Changing of patient's serum albumin at the follow-up time compare to serum albumin before surgery | on the 3rd, 6th, and 12th month after surgery | |
Secondary | Hemoglobin | Changing of patient's hemoglobin at the follow-up time compare to hemoglobin before surgery | on the 3rd, 6th, and 12th month after surgery | |
Secondary | Changing of Gastric remnant gastritis | Grade of gastric remnant gastritis according to RGB classification (for endoscopy) and updated Sydney classification (for histology) | on the 6th, and 12th month after surgery | |
Secondary | Changing of Residual food | Grade of Residual food according to RGB classification via endoscopy | on the 6th, and 12th month after surgery | |
Secondary | Changing of bile reflux | Finding of bile reflux according to RGB classification via endoscopy | on the 6th, and 12th month after surgery | |
Secondary | Changing of GSRS score | Patient's quality of life evaluated using the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire | on the 3rd, 6th, and 12th month after surgery | |
Secondary | 6th month reflux esophagistis | Findings of reflux esophagitis according to Los Angeles classification via endoscopy | on the 6th month after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |